Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Baycol Withdrawal: Did Public Reaction Cause More Harm Than Drug?

Executive Summary

The public reaction to the withdrawal of Bayer's Baycol (cerivastatin) may have caused more harm than the toxicity associated with the drug, Duke Centers for Education & Research on Therapeutics Principal Investigator Robert Califf, MD, told a CERTs workshop in Chapel Hill, N.C., Jan. 8

You may also be interested in...

CERTS presentation on drug risk workshops

The Centers for Education and Research on Therapeutics will present the research and education agenda resulting from its five therapeutic risk workshops March 6 at the National Press Club in Washington, D.C., at 9 a.m. Workshops to date have covered risk communication, risk assessment and benefit assessment; risk communication & the media will be held on Jan. 7-8 and risk management on Jan. 13-14. The workshops are co-sponsored by CERTs, PhRMA, AHRQ and FDA (1"The Pink Sheet" July 8, p. 21)...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts